Table 1 Patient demographics and disease characteristics.
Characteristic | All patients (N = 47) |
|---|---|
Median age, years (range) | 65 (45–85) |
Median time since initial diagnosis, years (range) | 6.2 (1.1–22.7) |
Gender, male, n (%) | 27 (57.4) |
Race, n (%) | |
White | 42 (89.4) |
Black or African American | 3 (6.4) |
Asian | 1 (2.1) |
Other | 1 (2.1) |
ISS stage at study entry, n (%) | |
I | 23 (48.9) |
II | 12 (25.5) |
III | 7 (14.9) |
Unknown | 5 (10.6) |
ECOG performance status, n (%) | |
0 | 5 (31.9) |
1 | 30 (63.8) |
2 | 2 (4.3) |
Respiratory disorders at baseline, n (%) | |
Asthma | 8 (17.0) |
Bronchial hyperreactivity | 1 (2.1) |
COPD | 2 (4.3) |
At least 1 transplant, n (%) | 32 (68.1) |
Autologous stem cell transplant | 31 (66.0) |
Allogenic stem cell transplant | 2 (4.3) |
Number of prior linesa, median (range) | 3 (1–8) |
Prior treatments | |
Lenalidomide | 47 (100) |
Pomalidomide | 23 (48.9) |
Bortezomib | 46 (97.9) |
Carfilzomib | 11 (23.4) |
Daratumumab | 7 (14.9) |
Elotuzumab | 9 (19.1) |
Refractory status, n (%) | |
Last regimen | 41 (87.2) |
Lenalidomide | 41 (87.2) |
Pomalidomide | 23 (48.9) |
Bortezomib | 26 (55.3) |
Carfilzomib | 7 (14.9) |
Daratumumab | 7 (14.9) |
Elotuzumab | 9 (19.1) |
Immunomodulatory drug, proteasome inhibitor, and daratumumab | 7 (14.9) |
Lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab | 2 (4.3) |
High-risk cytogeneticsb, n (%) | 10 (21.3) |
Median number of cycles receivedc (range) | 9 (1–19) |
Overall median duration of exposure, weeks (range) | 36.9 (1–77) |
